All In Biotech

Drug Trial Radar · NCT04512235

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL Amyloidosis

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 281 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

281

Actual

Start

Nov 3, 2020

Primary completion

Apr 8, 2025

Study completion Apr 8, 2027

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated in patients with stage IIIa AL amyloidosis.

Conditions

  • AL Amyloidosis

Interventions

  • CAEL-101Drug

    The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.

  • PlaceboOther

    Commercially available 0.9% Normal Saline will be used as the placebo.

  • cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimenDrug

    According to institutional standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A Hierarchical Combination of Time to All-cause Mortality and Frequency of Cardiovascular Hospitalizations (CVHs) Analyzed by Win RatioTime frame: Day 1 through end of the participant's PETP (Participants were enrolled on a rolling basis. Therefore, the primary analysis for the study was conducted 18-49 months after the study randomization.)
  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through end of the participant's PETP (Participants were enrolled on a rolling basis. Therefore, the primary analysis for the study was conducted 18-49 months after the study randomization.)

Locations

110 sites in 19 countries. Site status is shown where the registry gives one.

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Duarte, California

  • Research Site

    Palo Alto, California

  • Research Site

    San Francisco, California

  • Research Site

    Jacksonville, Florida

  • Research Site

    Weston, Florida

  • Research Site

    Indianapolis, Indiana

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Rochester, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Seattle, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Box Hill, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    Westmead, Australia

  • Research Site

    Woolloongabba, Australia

  • Research Site

    Linz, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Anderlecht, Belgium

  • Research Site

    Leuven, Belgium

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.